DXCM Return on equity
Return on equity at Dexcom rose to 34.5% in fiscal 2025, the highest in the 5 years reported, from 27.6% in 2024.
Net income to common divided by average shareholders' equity (mean of opening and closing). Both inputs as filed.
SOURCE: us-gaap:NetIncomeLoss + us-gaap:StockholdersEquity · EDGAR CompanyFacts · CIK 1093557 · EDGAR ↗ · FY2021–FY2025 · ANNUAL
History AS FILED · DERIVATION SHOWN WHERE DERIVED
| Fiscal year | Net income | Avg equity | ROE |
|---|---|---|---|
| FY2025 | $836M | $2.4B | 34.5% |
| FY2024 | $576M | $2.1B | 27.6% |
| FY2023 | $542M | $2.1B | 25.8% |
| FY2022 | $341M | $2.1B | 16.3% |
| FY2021 | $217M | $2.0B | 10.6% |
More SAME DATA, OTHER VIEWS
Return on equity across coverage → · DXCM company view →
Revenue · Net income · Operating cash flow · Free cash flow · Capital expenditure · Cash & equivalents · Total assets · Shareholders' equity · Days sales outstanding
Not investment advice. Every figure on this page is an XBRL fact from the issuer's own SEC filings or an arithmetic over such facts with the method shown. No forecast is made; no posture is expressed.